SYHX 2001
Alternative Names: SYHX-2001Latest Information Update: 19 Aug 2022
At a glance
- Originator CSPC ZhongQi Pharmaceutical Technology
- Class Antineoplastics
- Mechanism of Action Protein-arginine N-methyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 27 Jul 2022 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Second-line therapy or greater) in China (PO) (NCT05407909)
- 15 Jun 2022 NMPA approves clinical trial application for SYHX 2001 in Solid tumors and Hematological tumors in December 2021
- 08 Jun 2022 Preclinical trials in Solid tumours in China (PO) prior to June 2022 (NCT05407909)